Technical Analysis for ALRN - Aileron Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 1.94 0.52% 0.01
ALRN closed up 0.52 percent on Friday, March 22, 2019, on 21 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Earnings due: Apr 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical ALRN trend table...

Date Alert Name Type % Chg
Mar 22 Narrow Range Bar Range Contraction 0.00%
Mar 22 NR7 Range Contraction 0.00%
Mar 22 Inside Day Range Contraction 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 21 Wide Bands Range Expansion 0.52%
Mar 20 Calm After Storm Range Contraction -7.18%
Mar 20 Upper Bollinger Band Walk Strength -7.18%
Mar 20 Wide Bands Range Expansion -7.18%
Mar 20 Upper Bollinger Band Touch Strength -7.18%
Mar 19 Calm After Storm Range Contraction -11.82%

Older signals for ALRN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Biopharmaceutical Cancer Biology Solid Tumors Cancers Inflammation Molecular Biology Tumor Cell Biology Metabolic Diseases Proteins Oncogenes Lymphomas Treatment Of A Range Of Cancers
Is ALRN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.86
52 Week Low 0.52
Average Volume 376,312
200-Day Moving Average 2.6081
50-Day Moving Average 1.5818
20-Day Moving Average 1.7575
10-Day Moving Average 1.958
Average True Range 0.2576
ADX 38.83
+DI 33.7955
-DI 13.4328
Chandelier Exit (Long, 3 ATRs ) 1.8272
Chandelier Exit (Short, 3 ATRs ) 2.1328
Upper Bollinger Band 2.2682
Lower Bollinger Band 1.2468
Percent B (%b) 0.68
BandWidth 58.116643
MACD Line 0.1218
MACD Signal Line 0.102
MACD Histogram 0.0198
Fundamentals Value
Market Cap 28.55 Million
Num Shares 14.7 Million
EPS -41.73
Price-to-Earnings (P/E) Ratio -0.05
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.11
Resistance 3 (R3) 2.10 2.03 2.08
Resistance 2 (R2) 2.03 1.99 2.04 2.07
Resistance 1 (R1) 1.99 1.97 2.01 2.00 2.06
Pivot Point 1.92 1.92 1.94 1.93 1.92
Support 1 (S1) 1.88 1.88 1.90 1.88 1.82
Support 2 (S2) 1.81 1.86 1.82 1.81
Support 3 (S3) 1.77 1.81 1.80
Support 4 (S4) 1.77